Yasuyuki Ishii
Founder at REGiMMUNE Corp.
Profile
Yasuyuki Ishii is the founder of REGiMMUNE Corp.
which was founded in 2006.
He is currently a Professor at Chiba University and a Member of both The American Association of Immunologists and The Japanese Society for Immunology.
Dr. Ishii's former positions include being a Principal at Riken Corp.
and Kirin Pharma Co. Ltd.
as well as a Researcher at La Jolla Institute for Allergy & Immunology.
He received his undergraduate, graduate, and doctorate degrees from Tokyo Institute of Technology.
Yasuyuki Ishii active positions
| Companies | Position | Start |
|---|---|---|
| Chiba University | Corporate Officer/Principal | - |
| The American Association of Immunologists | Corporate Officer/Principal | - |
| The Japanese Society for Immunology | Corporate Officer/Principal | 15/07/2009 |
REGiMMUNE Corp.
 REGiMMUNE Corp. Pharmaceuticals: MajorHealth Technology REGiMMUNE Corp. develops solutions for treating immune disorders. Its focus is on the discovery, development, and commercialization of immune regulatory therapeutics to treat life-threatening and debilitating conditions, including allergies, autoimmune diseases and transplantation. The firm's platform technology, reVax, induces immune tolerance in an antigen-specific manner through pharmacological induction of regulatory T (Treg) cells. It also develops products for preventing inhibitor formation in enzyme replacement therapies (ERT) and for celiac disease with undisclosed partners. The company was founded by Yasuyuki Ishii on March 3, 2006 and is headquartered in Tokyo, Japan. | Founder | 03/03/2006 |
Former positions of Yasuyuki Ishii
| Companies | Position | End |
|---|---|---|
| RIKEN CORPORATION | Corporate Officer/Principal | - |
La Jolla Institute for Allergy & Immunology
 La Jolla Institute for Allergy & Immunology Miscellaneous Commercial ServicesCommercial Services La Jolla Institute for Allergy & Immunology is a non-profit organization located in La Jolla, CA. The private company focuses on immunology research and aims to unravel the complexities of the immune system to tackle an array of diseases such as asthma, cancer, COVID-19, type 1 diabetes, and Parkinson's. The company is home to three research centers that focus on autoimmune conditions, cancer, and infectious diseases. The company offers various services such as bioinformatics, clinical studies, cryo-em, flow cytometry, histopathology, immunometabolism, microscopy & histology, and next-generation sequencing. The company also provides licensing opportunities and initiatives. The company was founded by Steve Pontell and is currently led by Erica Saphire as the CEO. | Corporate Officer/Principal | - |
Kirin Pharma Co. Ltd.
 Kirin Pharma Co. Ltd. Pharmaceuticals: MajorHealth Technology Kirin Pharma Co. Ltd. manufactures and sells pharmaceutical products. Its products include Nesp, Regpara Tablets, Espo, Phosblock and Gran. The company was founded in 2007 and is headquartered in Tokyo, Japan | Corporate Officer/Principal | - |
Training of Yasuyuki Ishii
| Tokyo Institute of Technology | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| RIKEN CORPORATION | Producer Manufacturing |
| Private companies | 5 |
|---|---|
| The American Association of Immunologists | |
Kirin Pharma Co. Ltd.
Kirin Pharma Co. Ltd. Pharmaceuticals: MajorHealth Technology Kirin Pharma Co. Ltd. manufactures and sells pharmaceutical products. Its products include Nesp, Regpara Tablets, Espo, Phosblock and Gran. The company was founded in 2007 and is headquartered in Tokyo, Japan | Health Technology |
REGiMMUNE Corp.
REGiMMUNE Corp. Pharmaceuticals: MajorHealth Technology REGiMMUNE Corp. develops solutions for treating immune disorders. Its focus is on the discovery, development, and commercialization of immune regulatory therapeutics to treat life-threatening and debilitating conditions, including allergies, autoimmune diseases and transplantation. The firm's platform technology, reVax, induces immune tolerance in an antigen-specific manner through pharmacological induction of regulatory T (Treg) cells. It also develops products for preventing inhibitor formation in enzyme replacement therapies (ERT) and for celiac disease with undisclosed partners. The company was founded by Yasuyuki Ishii on March 3, 2006 and is headquartered in Tokyo, Japan. | Health Technology |
| The Japanese Society for Immunology | |
La Jolla Institute for Allergy & Immunology
La Jolla Institute for Allergy & Immunology Miscellaneous Commercial ServicesCommercial Services La Jolla Institute for Allergy & Immunology is a non-profit organization located in La Jolla, CA. The private company focuses on immunology research and aims to unravel the complexities of the immune system to tackle an array of diseases such as asthma, cancer, COVID-19, type 1 diabetes, and Parkinson's. The company is home to three research centers that focus on autoimmune conditions, cancer, and infectious diseases. The company offers various services such as bioinformatics, clinical studies, cryo-em, flow cytometry, histopathology, immunometabolism, microscopy & histology, and next-generation sequencing. The company also provides licensing opportunities and initiatives. The company was founded by Steve Pontell and is currently led by Erica Saphire as the CEO. | Commercial Services |
- Stock Market
- Insiders
- Yasuyuki Ishii
